Literature DB >> 15167989

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

J Jaime Caro1, Khajak J Ishak, Krista F Huybrechts, Gabriel Raggio, Christel Naujoks.   

Abstract

BACKGROUND: Clinical trials have demonstrated that drug therapy can reduce osteoporosis-related fracture risk in women over 50 years of age. Noncompliance could considerably limit the effectiveness observed in actual practice, however. The objective of this study was therefore to estimate fracture risk in relation to compliance with osteoporosis medication in actual practice.
METHODS: Demographic, prescription drug use, physician services, and hospitalization information for women with osteoporosis who were dispensed an osteoporosis medication between 1996 and 2001 was obtained from the Saskatchewan health data files. Compliance to treatment was defined as drug available to cover 80% of the time. Subsequent fractures were identified via hospitalizations or physician contacts with a relevant diagnostic or procedure code. The risk of fractures in relation to compliance was examined using a Cox proportional hazards model with time-dependent covariates. The impact of other patient characteristics, including age, having suffered a prior fracture, and prior use of osteoporosis medication and steroids, was also examined.
RESULTS: 11,249 women suffering from osteoporosis were identified with a mean age at the time of the index prescription of 68.4 years and average follow-up of 2 years. The overall fracture rate was 4.5% per year. Patients who complied experienced a 16% lower fracture rate. This association was maintained within subgroups and after controlling for other patient characteristics that independently predict the fracture rate.
CONCLUSION: These results indicate that improving compliance in actual practice may significantly decrease osteoporosis-related fracture risk.

Entities:  

Mesh:

Year:  2004        PMID: 15167989     DOI: 10.1007/s00198-004-1652-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  18 in total

1.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment.

Authors:  R Tamblyn; T Reid; N Mayo; P McLeod; M Churchill-Smith
Journal:  J Clin Epidemiol       Date:  2000-02       Impact factor: 6.437

2.  A systematic review of the associations between dose regimens and medication compliance.

Authors:  A J Claxton; J Cramer; C Pierce
Journal:  Clin Ther       Date:  2001-08       Impact factor: 3.393

Review 3.  Treatment of postmenopausal osteoporosis.

Authors:  R Eastell
Journal:  N Engl J Med       Date:  1998-03-12       Impact factor: 91.245

Review 4.  The use of claims databases for outcomes research: rationale, challenges, and strategies.

Authors:  B R Motheral; K A Fairman
Journal:  Clin Ther       Date:  1997 Mar-Apr       Impact factor: 3.393

5.  Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles.

Authors:  N S Rawson; E Malcolm; C D'Arcy
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-05       Impact factor: 4.328

Review 6.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

7.  Identification of fractures from computerized Medicare files.

Authors:  W A Ray; M R Griffin; R L Fought; M L Adams
Journal:  J Clin Epidemiol       Date:  1992-07       Impact factor: 6.437

Review 8.  Pharmacologic therapy for the treatment and prevention of osteoporosis.

Authors:  B McClung; M McClung
Journal:  Nurs Clin North Am       Date:  2001-09       Impact factor: 1.208

9.  Validity of rheumatoid arthritis diagnoses listed in the Saskatchewan Hospital Separations Database.

Authors:  P Tennis; C Bombardier; E Malcolm; W Downey
Journal:  J Clin Epidemiol       Date:  1993-07       Impact factor: 6.437

10.  Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles.

Authors:  N S Rawson; E Malcolm
Journal:  Stat Med       Date:  1995-12-30       Impact factor: 2.373

View more
  179 in total

1.  Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations.

Authors:  Milica Nikitovic; Daniel H Solomon; Suzanne M Cadarette
Journal:  Ther Adv Chronic Dis       Date:  2010-11-01       Impact factor: 5.091

2.  Efficacy of ibandronate: a long term confirmation.

Authors:  Ombretta Di Munno; Andrea Delle Sedie
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

3.  Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

Authors:  D L Kendler; M R McClung; N Freemantle; M Lillestol; A H Moffett; J Borenstein; S Satram-Hoang; Y-C Yang; P Kaur; D Macarios; S Siddhanti
Journal:  Osteoporos Int       Date:  2010-09-09       Impact factor: 4.507

4.  Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).

Authors:  E Landfeldt; O Ström; S Robbins; F Borgström
Journal:  Osteoporos Int       Date:  2011-02-01       Impact factor: 4.507

5.  Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

Authors:  V Rabenda; R Mertens; V Fabri; J Vanoverloop; F Sumkay; C Vannecke; A Deswaef; G A Verpooten; J Y Reginster
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

6.  The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.

Authors:  P Hadji; D Felsenberg; M Amling; L C Hofbauer; J A Kandenwein; A Kurth
Journal:  Osteoporos Int       Date:  2013-10-03       Impact factor: 4.507

7.  Bisphosphonates for the treatment of osteoporosis: insights for clinicians.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

8.  Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.

Authors:  K Briot; P Ravaud; P Dargent-Molina; M Zylberman; S Liu-Leage; C Roux
Journal:  Osteoporos Int       Date:  2008-07-26       Impact factor: 4.507

9.  Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures.

Authors:  V Rabenda; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-01-16       Impact factor: 4.507

Review 10.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.